CA-EAG-LABORATORIES
9.12.2020 14:02:15 CET | Business Wire | Press release
EAG Laboratories is pleased to announce the completed installation of a ThermoFisher Scientific Themis Z Transmission Electron Microscope (TEM) at our Silicon Valley facility. This next generation, ultra-high-resolution TEM is the first available in an independent laboratory in North America and is the second Themis Z owned by EAG Laboratories.
The Themis Z is a monochromated, probe-corrected TEM operated in an electron energy range of 30-300 kilovolts. Outside of its pure imaging capabilities, the microscope provides unprecedented access to physical and chemical properties for advanced materials research. With this technology, EAG scientists can provide our clients with:
- Sub-atomic spatial resolution
- State-of-the-art chemical analysis
- Revolutionary mapping capability for a wide variety of physical material properties
- Improved atomic resolution for compound semiconductors, atomic layer etching and advanced node devices
This leading edge TEM gives EAG Laboratories’ clients the highest resolution and deeper insights into the materials structure of their devices, which will increase their ability to improve device performance and reduce time to market. The Themis Z complements the company’s existing global microscopy services and strengthens its position as the world leader in advanced microscopy services.
EAG Laboratories is delighted to offer its clients data analysis along with the highest resolution images commercially available from a TEM. The company can now serve its clients in North America, Europe and Asia with these powerful advanced imaging capabilities coupled with its global scientific microscopy staff to solve both the routine and the most challenging materials analysis problems.
About EAG Laboratories
EAG Laboratories is the global leader in materials and engineering sciences and supports thousands of clients with 20+ locations throughout Europe, Asia, and the U.S. For more information visit eag.com. EAG Laboratories’ parent company, Eurofins Scientific, is a multi-billion global leader in scientific testing services with a portfolio of over 200,000 validated analytical methods.
About Eurofins – the global leader in bio-analysis
With over 50,000 staff across a network of more than 800 laboratories in over 50 countries , Eurofins’ companies offer a portfolio of over 200,000 analytical methods .
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 11:00:00 CEST | Press release
Acquisition adds widely adopted data observability and reliability capabilities to the Boomi Enterprise Platform, giving enterprises the data quality and governance required to operationalize AI Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key TakeawaysWhat Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-sou
Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo
EchoMark Launches European Operations and Partner Ecosystem19.10.2026 10:00:00 CEST | Press release
In response to growing demand from customers, the company is making its invisible forensic watermarking platform fully available in-region, with GDPR-compliant data residency to deliver leak attribution throughout Europe. EchoMark, the award winning invisible forensic watermarking company that identifies the source of information leaks, often in minutes, today announced the launch of its European operations. The full EchoMark platform is now available with European Union data residency, giving customers the option to run watermarking, administration, and leak investigations entirely on EU-based infrastructure. EchoMark has also entered into a partnership with Nomios, a leading European cybersecurity services provider, to deliver, deploy, and support the platform across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909554797/en/ EchoMark is also investing in the wider European insider risk community. The compa
Sagemcom Unveils Its New-Generation of VSB (Video Soundbox), Now Bringing Home Cinema and Karaoke to Every Living Room, First Deployed by DNA in Finland19.10.2026 10:00:00 CEST | Press release
Sagemcom announces the immediate availability of the new generation of VSB (Video Soundbox). Since its launch, operators around the world have chosen Video Soundbox to offer their customers a 4K set-top box and speakers combined in a single device. Building on this success, Sagemcom introduces its new VSB that takes home entertainment one step further. It is the world’s first set-top box for operators based on Broadcom’s BCM74116 SoC to be deployed. The VSB now offers deeper bass and wider sound spatialization for an even more immersive experience. Thanks to audio designed by Bang & Olufsen and Dolby Atmos, the sound is pure, powerful and multidimensional for all types of content. Dolby Vision brings true colors and sharp pictures. Today, the VSB goes far beyond the traditional TV experience. It can be further enhanced with Wireless Surround Speakers. Available as an option, they extend the sound across the entire room: films and series take on a true cinema dimension, while live sport
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 00:05:00 CEST | Press release
Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibodyBoth investigational therapies are being evaluated in ongoing Phase 3 programsIncyte will host an investor event and webcast on Monday, October 26, 2026 from 7:30 – 9:00 CET / 2:30 – 4:00 p.m. ET Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom